阿巴洛肽治疗三个月快速改善骨形成与骨密度:对骨科术前骨健康优化的意义
该研究为两项随机试验的事后分析,评估阿巴洛肽(ABL)治疗男性和绝经后骨质疏松患者3个月时骨密度(BMD)和骨转换标志物(BTM)的早期变化。结果显示,治疗3个月时股骨颈、全髋和腰椎BMD均显著增加,1个月时P1NP升高超过三倍,提示ABL可能用于择期骨科术前骨健康优化(BHO)。
要点
- ABL治疗3个月时男性和绝经后女性腰椎BMD分别增加4.14%和4.42%。
- 治疗1个月时血清P1NP较基线升高超过三倍,骨形成持续12个月。
- 3个月ABL对择期骨科术前BHO有前景,但需进一步研究。
核心结论
- 皮下注射ABL(80 µg/天)治疗3个月可使男性和绝经后骨质疏松患者BMD显著增加,增幅与骨折风险降低相关。
- 骨形成在1个月时增加并持续12个月。
- 三个月ABL治疗对骨强度和骨质疏松相关手术并发症的效果需进一步研究。
研究设计与样本
- 两项随机ABL试验的事后分析,纳入149名男性和250名绝经后女性骨质疏松患者,ABL治疗12个月。
- 主要终点为3个月时股骨颈、全髋和腰椎BMD平均百分比变化,同时评估BTM(P1NP和CTX)。
主要发现
- 3个月时男性股骨颈、全髋、腰椎BMD平均(SD)百分比增幅分别为1.79(0.35)、1.26(0.26)、4.14(0.43)。
- 3个月时女性股骨颈、全髋、腰椎BMD平均(SD)百分比增幅分别为1.55(0.28)、1.78(0.21)、4.42(0.34)。
- 与基线相比,女性和男性1个月时血清P1NP升高超过三倍。
临床怎么用
- 对于需择期骨科手术的骨质疏松患者,可考虑使用ABL进行术前骨健康优化,3个月可能观察到BMD改善。
- ABL治疗期间应监测骨转换标志物如P1NP以评估早期骨形成反应。
局限性
- 本研究为事后分析,结果需在前瞻性研究中验证。
- 原文未报告ABL对骨强度或手术并发症的直接证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: How long to delay orthopedic surgery for preoperative BHO using ABL remains unclear. MAIN FINDING: ABL results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis. ABL shows promise for preoperative BHO in elective orthopedic surgery patients, but further research is required. PURPOSES: This study aims to assess the early response to abaloparatide (ABL) in men and postmenopausal women with osteoporosis at high risk for fracture to inform its potential role in preoperative bone health optimization (BHO). We aim to assess changes in bone mineral density (BMD) by three months and early changes in bone turnover markers (BTMs). METHODS: A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed. The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine. BTMs P1NP and CTX were also assessed. RESULTS: At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively. In women, mean BMD percent increases at the same sites were 1.55 (0.28), 1.78 (0.21), and 4.42 (0.34) respectively. Compared with baseline, serum P1NP increased over threefold at 1 month in women and men. CONCLUSION: Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk. Bone formation is increased at 1 month and sustained for 12 months. Further research is required to investigate the effectiveness of a three-month ABL treatment period on bone strength and osteoporosis-related surgical complications in elective orthopedic surgery patients.
引用
- VanDerwerker NB, Mosiman S, Krueger D, et al. Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization. Osteoporos Int. 2026. PMID: 42498818. doi:10.1007/s00198-026-08126-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。